SEVERS DISEASE TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Market Size and Trends

The global Sever's Disease Treatment Market is estimated to be valued at USD 1.34 Bn in 2024 and is expected to reach USD 1.87 Bn by 2031, growing at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031.

To learn more about this report, request a free sample copy

The market is witnessing positive growth trends due to rising incidences of Sever's disease worldwide, and increasing participation of kids and teenagers in sports activities is a key factor driving the market growth. Additionally, growing awareness regarding the treatment options for Sever's disease is also contributing towards the market growth. Various technological advancements in the area of Sever's disease diagnosis and treatment like advanced imaging techniques and minimally invasive treatment procedures are further expected to propel the demand for Sever's disease treatment over the forecast period. However, non-invasive treatment alternatives for Sever's disease like rest, ice, stretching, and heel raises offers first line treatment in mild cases which might hamper the market growth to some extent.

Rising incidence of Sever's disease

The incidence of Sever's disease, a common cause of heel pain in active children, has been on the rise globally in recent years. Sever's disease is caused by inversion or plantar flexion injuries of the growth plate in the heel bone. As more children participate in sports and recreational activities at an early age, the rate of repetitive microtrauma to the heel has increased significantly. According to United Nations Children's Fund (UNICEF) data from 2020, childhood obesity is also on the rise in both developed and developing nations due to sedentary lifestyles and poor diets. Obese children are four times more likely to develop Sever's disease due to increased stress on the heel and ankle joints. As the occurrence of Sever's disease rises, there is growing demand for effective treatment options. Non-steroidal anti-inflammatory drugs and heel cradles/supports are commonly used to manage symptoms in mild to moderate cases. For more severe cases, corticosteroid injections and physical therapy focusing on muscle strengthening and mechanics re-training are increasingly being utilized.

Market Concentration and Competitive Landscape

To learn more about this report, request a free sample copy

Increasing adoption of inorganic growth strategies, such as product launches, by key market players are expected to drive the market growth over the forecast period. For instance, in September 2020, Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced that it had launched Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren Arthritis Pain in the U.S. Diclofenac Sodium Topical Gel 1%, is used for the temporary relief of arthritis pain of the hand, wrist, elbow, foot, ankle, and knee.

To learn more about this report, request a free sample copy

Lack of awareness in underdeveloped regions is significantly restraining the growth of the global Sever's disease treatment market. Sever's disease, also known as calcaneal apophysitis, is a common cause of heel pain in children. However, in many underdeveloped parts of the world, people have very limited knowledge about this medical condition and its treatment options. In such resource-constrained areas, healthcare facilities are usually basic and lack necessary infrastructure as well as medical expertise. Doctors and healthcare workers have limited access to continued medical education and updated knowledge about newer conditions and treatment protocols. As a result, cases of Sever's disease often go undiagnosed or are misdiagnosed. People in rural communities have very little understanding of childhood heel pain and its causes. They are unaware that simple measures like rest, ice application, stretches, and orthotics can effectively treat Sever's disease. Due to the lack of awareness, many children continue suffering in pain without seeking proper medical help.

Market Opportunities - Increasing online purchase of OTC drugs:

The increasing trend of purchasing over-the-counter (OTC) drugs online is having a substantial impact on the global Sever's disease treatment market growth. With the convenience of shopping from home, more people are opting to buy OTC medications and supportive devices for adolescent heel pain online rather than visiting a pharmacy in person. This shift to online purchasing has several consequences for companies operating in this market. It is expanding the potential customer base. Those who may not have easy access to reliable brick-and-mortar healthcare stores due to remote locations or other barriers can now purchase Sever's disease treatment options online. This is allowing companies to reach more customers globally. Furthermore, the online medium makes it simpler to compare products and prices within a few clicks. Customers can easily research treatment alternatives and select the option that best suits their needs, based on factors like cost, product ratings, special offers etc. This increases competition in the market and forces companies to improve product quality and offer competitive deals.

To learn more about this report, request a free sample copy

The disease type segment includes acute and chronic. The acute segment is expected to hold 54.8% market share in 2024 owing to the high prevalence of acute onset cases worldwide. According to the World Health Organization, approximately 60% of all pediatric ankle injuries presenting to hospitals globally are acute Sever's disease flare ups. This high incidence rate can be attributed to the physical and physiological changes occurring during puberty which places high stresses on the growth plates of the heel bone in children aged between 8-14 years. The acute segment is also experiencing strong growth driven by increasing participation of children in sports and extracurricular activities. Studies show children today spend more time engaging in high impact sports like soccer, basketball compared to previous generations. The physical demands of such sports combined with long training hours have been correlated to a surge in overuse injuries to the calcaneus apophysis, the growth plate affected in Sever's disease. Additionally, increased awareness among parents about early intervention options is propelling individuals to actively seek treatment for timely management of acute cases.

Insights, By Type: Increased suitability for continuous monitoring applications

The type segment includes over-the-counter and prescription. Prescription is anticipated tohold 53.9% market share in 2024 due to the severe nature of the condition in many cases. According to studies by the American Academy of Orthopaedic Surgeons, approximately 10-15% of children aged 2-12 will develop Sever's disease, which is an inflammation of the growth plate in the heel bone that causes swelling, pain and tenderness in the heel and arch area of the foot. While over-the-counter treatments such as rest, ice, stretching, and arch supports can help relieve mild symptoms, prescription medications and orthotics are usually necessary for moderate to severe cases. Prescription treatments often involve nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen to reduce pain and swelling. The World Health Organization recommends NSAIDs as first-line treatment for managing mild to moderate pain associated with Sever's disease. Prescription orthotics may also be provided to realign the foot and redistribute weight away from the tender heel area.

Insights, By Drug: Widespread usage promotes Diclofenac growth

The drug type segment includes diclofenac, etodolac, indomethacin, celecoxib, and others. The Diclofenac segment holds the dominant position in the market and is anticipated to hold 47.3% market share in 2024. As reported by the American Academy of Orthopaedic Surgeons, Diclofenac is one of the most commonly prescribed medications for Sever's disease due to its potent pain-relieving properties. Diclofenac works by blocking cyclooxygenase enzymes, which are responsible for producing prostaglandins involved in pain and inflammation. Its anti-inflammatory effects make it highly effective at reducing swelling and pain associated with Sever's disease. Diclofenac sees widespread usage in both oral and topical formulations. The oral versions are taken two to three times daily as needed, allowing for flexible on-demand dosing. Topical gels and creams provide targeted pain relief directly at the site of injury. Additionally, Diclofenac's generic status has made it an affordable option for many patients and health systems. These combined factors of clinical efficacy, formulation versatility and cost have contributed to Diclofenac gaining the leading market share position.

Regional Insights

To learn more about this report, request a free sample copy

North America has dominated the global Sever's disease treatment market and is expected to hold 38.3% of the market share in 2024. This can be attributed to the rising pediatric population and increased awareness regarding Sever's disease in the region. The U.S. holds the majority market share in North America owing to high diagnosis and adoption rates of treatment options for Sever’s disease. Further, developed healthcare infrastructure and availability of advanced treatment methods have been propelling growth. Key players have also strengthened their presence and product portfolios in the region through acquisitions and partnerships with local providers.

Asia Pacific has emerged as the fastest growing regional market for Sever's disease treatment in recent times. Rapidly developing economies like India and China have played a pivotal role in driving the market in APAC. This can be accredited to growing medical tourism, widening patient pool, and improving access to healthcare facilities. Rising disposable incomes have also increased the affordability of treatments. Further, increasing focus of international players towards penetrating untapped opportunities available in the region through investments and collaborations with domestic players is aiding market expansion. Japan holds an important position in the Asia Pacific market due to the high penetration of foot screening programs and a developed healthcare infrastructure.

Market Report Scope

Key Developments

• On November 3, 2023, Hisamitsu Pharmaceutical, a pharmaceutical company, launched the Salonpas Diclofenac Patch 1% in Singapore. It is the first in the Salonpas line to use diclofenac, a clinically-used ingredient that is powerful and efficacious and penetrates to alleviate pain at its core. Each patch measures 7cm by 10cm and contains 15mg of diclofenac sodium. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) used to relieve severe, persistent pain, and relieve symptoms such as inflammation, swelling, stiffness, and joint pain.
• On January 3, 2023, Yaral Pharma Inc., the subsidiary company of IBSA Institut Biochimique SA, a pharmaceutical company, announced the launch of diclofenac epolamine topical system 1.3%, the authorized generic of IBSA Pharma’s Flector (diclofenac epolamine) topical system. Diclofenac epolamine topical system 1.3% is a prescription nonsteroidal anti-inflammatory (NSAID) medicated patch indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.
• In December 2022, Lupin, a pharmaceutical company, announced that it had launched, Diclofenac Sodium Topical solution in the U.S. The drug is generic version of Pennsaid of Horizon Pharma Therapeutics, a pharmaceutical company. Diclofenac Sodium Topical solution is used to relieve pain from arthritis in certain joints such as those of the knees, ankles, feet, elbows, wrists, and hands.

*Definition: Sever’s Disease, also known as “Calcaneal Apophysitis,” is inflammation of the growth plate at the heel (calcaneus). The disease occurs because the calcaneus is not fully developed until approximately 14-15yrs old in girls and 15-16yrs old in boys. The growth plate is made up of cartilage and is more prone to injury due to the tissue being weaker than the surrounding bone.

Market Segmentation

•  Disease Type Insights (Revenue, USD BN, 2019 - 2031)
  • Acute
  • Chronic
•  Drug Insights (Revenue, USD BN, 2019 - 2031)
  • Diclofenac
  • Etodolac
  • Indomethacin
  • Celecoxib
  • Others
•   Application Insights (Revenue, USD BN, 2019 - 2031)
  • Over-the-counter
  • Prescription
•  Route Of Administration Insights (Revenue, USD BN, 2019 - 2031)
  • Oral
  • Parenteral
  • Others
•  Distribution Channel Insights (Revenue, USD BN, 2019 - 2031)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD BN, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • AstraZeneca
  • Horizon Therapeutics plc
  • Sanofi
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Inc.
  • LEO Pharma A/S
  • AbbVie Inc.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Lonza
  • Lupin
  • Dr. Reddy’s Laboratories Ltd.
  • IBSA Institut Biochimique SA